Tamtuvetmab
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA) . Tamtuvetmab has been approved by veterinary[1][2].
Product Specifications
CAS Number
1608122-71-9
Product Name Alternative
AT-005
UNSPSC
12352203
Target
NF-κB
Type
Inhibitory Antibodies
Related Pathways
NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tamtuvetmab.html
Purity
97
Solubility
10 mM in DMSO
Smiles
[Tamtuvetmab]
Molecular Weight
(146.346 kDa)
References & Citations
[1]Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9 (1) :e49. |[2]Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740768-100 1x 100 µL
GnRH-Receptor (LHRH Receptor) (GNRHR/768), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
